INTRODUCTION
Mitochondrial function in neurons is critical for generating ATP (Brand and Nicholls, 2011; Vafai and Mootha, 2012) , producing and detoxifying reactive oxygen species (ROS) (Zorov et al., 2014) , buffering Ca 2+ , mediating cell apoptosis, and synthesizing and releasing neurotransmitters (Duchen, 2000) . Owing to these and other critical functions within high energy-demanding neurons, impairments in the mitochondrial system are associated very broadly with brain disorders (Connolly et al., 2018; Cai and Tammineni, 2016; Lezi and Swerdlow, 2012) . These impairments include reduced mitochondrial numbers, membrane potential (DJ m ), respiratory capacity, and ATP production, coupled with increased fragmentation and decreased synaptic function (Wang et al., 2009; Cai and Tammineni, 2017; Perez Ortiz and Swerdlow, 2019) . Enhancing the function of neuronal mitochondria with small molecule therapeutics may offer effective treatment for these diseases (Alam et al., 2015; Moreira et al., 2010) . However, prior screens used to identify such potential therapeutics have employed established cell lines, yeast, or fibroblasts (Kitami et al., 2012; Mortibouys et al., 2013) . Given the unique architecture and physiology of neurons and the established differences in mitochondria across cell types (Calvo et al., 2016) , screens for neuronal mitotherapeutics are best performed in neurons themselves. Thus we have searched for chemical enhancers of neuronal mitochondrial function using mammalian primary neurons to conduct a high-throughput screen (HTS).
We report here the development of an assay and results from a small molecule screen using neurons cultured from mouse brain and measuring DJ m , which provides the driving force on ATP synthase. Secondary screens for ATP production were employed to funnel the initial set of molecules, which were then tested for their effects on mitochondrial respiration and aspects of mitochondrial dynamics, including mitochondrial length and circularity, the latter being a morphological measure of mitochondrial health. The final set of molecules were subsequently shown to protect mitochondrial function from the insults of increased oxidative stress and an Alzheimer-like cellular environment produced in a genetic mouse model of Alzheimer disease. Strikingly, several classes of molecules had efficacy across these assays, including local anesthetics, estrogen agonists, isoflavones, and tricyclic antidepressants. These molecules offer starting points to probe the intricacies of the neuronal mitochondrial system and for potential mitotherapeutics.
RESULTS

Primary Neuron Assays for Inner Mitochondrial Potential and ATP Generation
The inner mitochondrial membrane potential (DJ m ) and proton gradient generated by proton pumps during oxidative phosphorylation (OXPHOS) provide the energy to drive ATP synthesis. DJ m is widely For the primary screen, we incubated 13 days in vitro (DIV13) primary neurons with 10 nM TMRM for 90 min to reach equilibrium before pin-tooling compounds from the Spectrum Collection from MicroSource. This library contains 2,400 structurally diverse compounds, the majority of which are marketed drugs or compounds in clinical trials. All compounds were assayed in quadruplicate at 12.5 mM, and mitochondria-localized TMRM fluorescence (Figures 1A-1A 00 ) was measured at 4 and 24 h to identify compounds that have acute or delayed effects on DJ m ( Figure 1B ). We predicted that acute hits might be compounds that directly and rapidly target the electron transport chain to modulate the efficiency of OXPHOS, whereas compounds with a delayed effect might modulate gene expression or signaling pathways to enhance mitogenesis and/or OXPHOS activities. From the 2,400 tested compounds, 16 (0.6%) were selected as putative hits increasing TMRM fluorescence at 4 h and 135 compounds (5.6%) increasing TMRM fluorescence at 24 h. Eleven of the compounds exhibited significant effects at both 4 and 24 h (>3 Z scores for the inner wells, >2.5 Z scores for the outer wells, Figures 1C-1D 00 ).
We rescreened all 4-and 24-h TMRM hits alongside 40 DMSO control wells and 134 TMRM-negative compounds randomly selected from the original screen in a blind manner. There was a correlation of compound effect size on 24-h TMRM fluorescence between the primary screen and rescreen (R 2 = 0.63, Figure 1E ). Of the 135 compounds 120 were confirmed as hits enhancing TMRM fluorescence at 24 h (89%). Of these, 112 (93%; Table S1) proved positive using the orthogonal assay for ATP production, elevating ATP levels by $15% (>3 Z scores) compared within within-plate DMSO controls ( Figure 1F ). Although the correlation of ATP and TMRM effect sizes was more modest (R 2 = 0.46), the putative hits significantly enhanced TMRM fluorescence and ATP production compared with non-hit compounds or DMSO-treated controls ( Figure 1F ). Only two of the 16 (13%) compounds that elevated TMRM fluorescence at 4 h increased ATP levels. To probe the relationship between TMRM signal and ATP production, we compared the correlation coefficient between the TMRM fluorescence of all rescreened compounds and ATP production at 4 and 24 h. We found a very weak correlation between these two parameters for 4 h of incubation (R 2 = 0.16, p < 0.0001, Figure S4C ) and a modest correlation (R 2 = 0.46, p < 0.0001, Figure 1F ) for 24 h, indicating a general trend between the measured whole-well TMRM signal and higher energetics of the neuronal population. We focused our subsequent studies on hits selected after a 24-h incubation with neurons given the stronger relationship between TMRM fluorescence and ATP generation. Using this incubation time, the results indicate that increased DJ m is a good, inexpensive surrogate for detecting elevated levels of ATP within neurons.
Structural and Functional Diversity and Potency of Modulators of Mitochondrial Function
We found that many of the confirmed 24-h TMRM/ATP hits were structurally related and grouped them using hierarchical clustering and Tanimoto similarities into several clusters ( Figure 2 ). We also discovered that some of the structural clusters contain compounds with a similar therapeutic use (Figures 2 and S5-S7;  Table S2) . Surprisingly, nine of the hit compounds are topical/local anesthetics (primarily in Cluster 3, orange shading in Figure 2 ) that increase neuronal mitochondrial DJ m and elevate ATP. Owing to this novel finding, we included representatives from this group in subsequent experiments (lidocaine, benoxinate, dyclonine). Although only two isoflavone compounds were identified (Cluster 4, green), genistein was reported by Ding et al. (2011) to increase DJ m in primary cortical neurons treated with Ab peptide. Therefore, we employed genistein in later experiments as a putative positive control compound. Cluster 4 also contains many steroid hormone receptor modulators and two COX inhibitors (gray). Estrogen derivatives were previously shown to contain neuro-and mitochondria-protective activity (Mortibouys et al., 2013 , Sherman and Bang, 2018 , Grimm et al., 2014 , Irwin et al., 2008 Nilsen et al., 2007) , but the mitochondrial effect of COX inhibitors was unexpected. Thus, we chose celecoxib for further characterization. Cluster 5 is composed of three indole alkaloids that have alpha-blocker activity (brown). One of them, yohimbine was previously found to be neuroprotective by inducing the NRF2-mediated antioxidant response (patent WO2012149478A3). Therefore, we included yohimbine in follow-up experiments as a potential positive control and to explore this activity further. Cluster 6 contains a collection of structurally similar alpha/ beta-blockers for the treatment of high blood pressure and heart diseases (anti-adrenergics, brown), from which we chose carvedilol and naftopidil for further tests. We also highlight the interesting identification of several anti-psychotics and classic tricyclic antidepressants (pink), anti-cholinergics (purple), and anti-dopaminergic/anti-serotoninergic compounds (yellow) in Clusters 7 and 8, whose unanticipated functional modulation of mitochondria made them intriguing compounds for additional experiments. We added the antibiotic phenyl-aminosalicylate (Cluster 3, blue) and two well-known antiparkinsonian agents (Cluster 9, anti-cholinergic, purple) for some subsequent experiments to begin exploring how this rich set of structurally and functionally diverse compounds modulates the function of neuronal mitochondria. Table S2 ) of selected compounds revealed that the EC 50 's for TMRM fluorescence and/or ATP enhancement were generally between 0.1 and 5 mM. Effect sizes were measured ; the image (60X) at the right (A 00 ) illustrates neuronal mitochondria at a higher power including the intense, perinuclear mitochondria. n = nucleus. Scale bar, 400 mm for (A and A 0 ) and 20 mm for (A 00 ). (B) High-throughput screening pipeline for small molecule enhancers of neuronal mitochondrial function. Primary screen: Primary neurons were isolated, plated, and cultured to DIV13 and loaded with TMRM before compounds were added with a pin-tool. At 4 and 24 h after compound addition the neurons were washed and TMRM fluorescence was read. Orthogonal screen: TMRM hits selected from the primary screen were rescreened and tested for their ability to enhance neuronal ATP production in an orthogonal screen. Functional analysis: TMRM/ATP positive hits were clustered by structural similarity. Representative hits from main structural clusters were further assayed for dose response, effects on oxygen consumption (OCR), mitochondrial morphology, neurite sprouting, and protection to neurons against insults associated with neurodegenerative diseases. (C-D 00 ) (C and D) Scatterplots of normalized Z scores (Z) of TMRM fluorescence, (C 0 and D 0 ) as zoomed in (orange shading in C and D) to eliminate most toxic and autofluorescent reads, and (C 00 and D 00 ) effect size of TMRM signals at 4-(C-C 00 ) and 24-h incubation (D-D 00 ). Z score = (value compound -m plate )/s plate . Effect size = (value compound -m plate )/m plate . Z score and effect size (E) values for each compound were calculated per plate using population statistics from four replicate plates. We used the population of ''inactive'' compound-treated wells as the control; see Figures S3A and S3B for details on the ''non-DMSOcontrol'' statistical approach. Results are plotted as means G SEM from the quadruplicates. Putative hits that increased intracellular TMRM intensity above the plate mean (m plate ) by 3s for the inner wells and by 2.5s for the outer wells were selected for rescreen. Distribution histograms of Z score and effect size are shown on the right side of (C 0 , C 00 , D 0 , and D 00 ). Arrowheads indicate the subpopulation identified as putative hits. (E and F) Orthogonal screen of putative TMRM hits measuring ATP production; 135 putative hits with effects at 24 h (red) from the primary screen were retested alongside 134 randomly selected non-hit compounds (black) and 40 DMSO controls (gray). The compound effect at 24-h incubation on TMRM fluorescence and ATP production was normalized to DMSO controls on the same plate in the rescreen. Data were calculated as (value compound -m DMSO )/ m DMSO . The 135 putative 24-h hits (red) plus 134 non-hits (black) are shown in the plot. Each point represents the mean from four replicate wells. (E) Correlation plot of 24-h TMRM fluorescence from the primary screen and rescreen. Linear regression fitted to values generated from the plotted 269 compounds (black line, R 2 = 0.63). The distribution of normalized TMRM effect size in wells treated with putative hits (red), non-hits (black), and DMSO (gray) is shown along the abscissa. One-way ANOVA followed by Dunn's post hoc was used for comparisons with the DMSO control and non-hit groups. ****p < 0.0001. (F) Correlation plot of compound effects on ATP production and TMRM fluorescence. The distribution of compound effect size on TMRM fluorescence and ATP production after 24-h incubation is shown in the histograms across the abscissa and ordinate, respectively. The putative 24-h TMRM hits are labeled in red, non-hits in black, and DMSO-treated wells in gray. Linear regression fitted to values generated from the plotted 269 compounds (black line, R 2 = 0.46). One-way ANOVA followed by Dunn's post hoc was used for comparing with the DMSO control and non-hit groups. ****p < 0.0001. Compounds were selected as TMRM/ATP hits if the effect size for ATP generation was greater than 15% (>3s DMSO , dashed lines in E and F) in the orthogonal screen in addition to being confirmed as TMRM hits. between 15% and 30%. Nearly all compounds, apart from yohimbine, exhibited inverted-U-shaped responses suggesting mitochondrial toxicity at high concentrations. Neurons are highly sensitive cells, and most compounds have detrimental effects at high concentrations.
Dose response assays (Figures S5-S7;
Mitochondrial Functional Modulators Potentiate Respiration
The effects of the compounds on ATP generation suggested that they may increase mitochondrial respiration. To test this possibility, we selected yohimbine (indole alkaloid) and doxepin (tricyclic antidepressant) for the necessary and more complex, absolute oxygen consumption rate (OCR) experiments. OCR at baseline and in response to excess ADP/substrate (State3/3u) was measured and normalized to protein content (Salabei et al., 2014; Sims and Anderson, 2008) using primary neurons presented with compounds for 24 h. Primary neurons exposed to yohimbine or doxepin showed a weak, non-significant, but consistent trend toward an increased basal rate of respiration, potentially due to a modest increase in mitochondrial function and/or content (Figures 3A-3B 0 ). More importantly, we observed a significant increase of State 3 and 3u respiration stimulated by either Complex I or Complex II substrates in mitochondria from cultured neurons treated with yohimbine ( Figures 3A-3B 0 ) , and a significant increase with Complex I substrates for doxepin. We also took advantage of the water solubility of yohimbine to administer this compound to mice in drinking water across a period of 7 months. A similar respiratory increase was observed in mitochondria isolated from the whole brains of animals chronically treated with yohimbine ( Figures 3C and 3D ). We calculated the respiratory control ratios (RCRs, State 3/4 o ) to provide a broad index of mitochondrial function (Brand and Nicholls, 2011; Rogers et al., 2011) . State 3 respiration measures the maximal ability of mitochondria for substrate oxidation and ATP generation. State 4 o , with OCR measured in response to oligomycin challenge, measures proton leak. The ratio between these states is influenced by most functions of OXPHOS, thus providing a net measure of the tightness between respiration and phosphorylation. Yohimbine treatment significantly increased RCR with both Complex I and II substrates with both mitochondria from cultured neurons and isolated brain mitochondria (Figures 3A 0 , 3B 0 , 3C 0 , and 3D 0 ). Doxepin weakly increased RCR using Complex I, but not II, substrates in cultured neurons (Figures 3A 0 -3B 0 ). Collectively, the enhanced State 3 respiration and RCR with yohimbine and the weaker effects of doxepin indicate more efficient substrate oxidation, electron transport, coupling to OXPHOS, and a lower proton leak, indicating a higher respiration capacity and efficiency in the treated mitochondria. Moreover, we previously reported that the anesthetic dyclonine produces beneficial effects in similar cell culture and in vivo experiments . Thus, representative compounds from three classes of functional mitochondrial modulators-indole alkaloids, tricyclic antidepressants, and local/topical anesthetics-all enhance neuronal mitochondrial function. These modulators may be acting directly on mitochondria or indirectly by stimulating cell signaling pathways that influence mitochondrial function (Sherman and Bang, 2018; Tsvetkov et al., 2010) . However, the functional changes on mitochondria instilled by the tested compounds must be enduring and become independent of cytoplasmic signaling pathways, because increased function persists in permeabilized neurons and in mitochondria purified from cells.
Modulators of Neuronal Mitochondrial Function Alter Mitochondrial Morphology
To determine whether enhanced mitochondrial function is associated with mitochondrial morphological changes, we used a high-content assay developed in parallel to monitor aspects of mitochondrial dynamics in primary cultured neurons that conditionally express (Cre recombinase-dependent) mitochondrialtagged GFP and cytosolic tdTomato reporters . We monitored two aspects of neuritic mitochondrial dynamics: the health of mitochondria as measured by the average circularity of axonal mitochondria, because defective mitochondria targeted for mitophagy become circular in shape, and the balance between fission/fusion measured by the average length of dendritic mitochondria. We also determined whether the compounds induced neurite sprouting by measuring the total area of neurites within the collected images (see Methods). Figure 4 illustrates the results of surveying a collection of functional modulators selected from five different structural clusters ( Figure 2 ), quantified as robust Z scores relative to DMSO-treated control neurons. All the compounds tested showed a trend toward promoting Weighted Pair Group Method with Arithmetic Mean (WPGMA) clustering of the 112 confirmed TMRM/ATP 24-h hits into nine groups based on the Euclidean distance of Tanimoto similarities of their Morgan fingerprints with a cutoff at value 1.45 (red line). Representative chemical scaffolds for some clusters are highlighted in red. Shading: orange = local/topical anesthetics; green = isoflavones; gray = COX inhibitors; brown = alpha/beta blockers; pink = antipsychotics and tricyclic antidepressants; purple = anti-cholinergics; yellow = anti-dopaminergic/serotonergic compounds. more oblong mitochondria after 24 h, and they exhibited significant potency (Z score < À2.0) compared with the control after 48 h of treatment. Notably, the identified mitochondrial OCR enhancers yohimbine, dyclonine, and doxepin exhibited robust effects. These results provide evidence that the functional modulators promote healthier mitochondria using the morphological surrogate of circularity.
The tested compounds also promoted the lengthening of dendritic mitochondria to Z scores R 2.0 after 48 h of treatment. This observation is consistent with a report that mitochondrial fusion and fragmentation are associated with higher and lower DJ m values, respectively, in neuroblasts and stable cell lines (Sherman and Bang, 2018; Voccoli and Colombaioni, 2009 ). Yohimbine, dyclonine, pimozide, and penfluridol were also observed to increase neuritic area after 48 h of treatment.
Neuronal Mitochondrial Modulators Provide Protection against Insults Associated with Neurodegenerative Disorders
Given the strong relationship between mitochondrial dysfunction and brain disorders, we tested a group of functional mitochondrial modulators for their potential to protect against two neurodegeneration-associated insults: neurons subjected to increased oxidative stress and those expressing Alzheimer-causing gene variants (neurons from 3XTG mice). Adding tert-butyl hydroperoxide to the cultures to increase oxidative stress severely reduced TMRM fluorescence at concentrations above 50 mM and led to complete cell death at concentrations >100 mM ( Figure 5 ). Eight of the 10 compounds tested provided protection to the DJ m from the toxic effects of increased oxidative stress (Figures 5A-5A 00 ). Primary neurons isolated and cultured from 3XTG mice to DIV23 exhibited a $20% reduction in TMRM fluorescence normalized to protein content per well when compared with C57Bl/6J neurons (Figures 5B-5B 00 ). All compounds tested significantly increased DJ m in the presence of the insult to the level observed for control B6 neurons ( Figure 5B") . Remarkably, many of the compounds tested protect against both insults, including yohimbine, genistein, dyclonine, benoxinate, lidocaine, phenyl-4-amino salicylate, pimozide, and doxepin (Figures 5A 00 and 5B 00 ).
DISCUSSION
Our mitochondria-targeted TMRM/ATP high-throughput assay and screen using cultured primary neurons successfully identified multiple structural and functional clusters of compounds that enhance the function of neuronal mitochondria. The most surprising observation made concerns the large number and diversity of the compounds identified that potentiate mitochondrial function. Included among the modulators are the hormone derivatives yohimbine and genistein, which, consistent with published results, provided beneficial effects on mitochondrial function and overall neuronal health. These compounds stand out as positive controls for use in future HTSs that assay mitochondrial function. The most interesting and novel categories of hits include topical/local anesthetics as represented by dyclonine, classic tricyclic antidepressants as represented by doxepin, and the anti-psychotics as represented by pimozide and penfluridol. These results offer the prospect that molecules of these classes may offer protection against diseases that are associated with neuronal mitochondrial dysfunction. In addition, they Mitochondrial respiration in primary neurons exposed to compounds identified as mitochondrial functional enhancers from the screen. Before OCR measurements, DIV13 neurons were treated for 24 h with DMSO (0.1%) or the compounds (10 mM). Neurons were gently permeabilized using 25 mg/mL saponin (Sa). OCR measured from permeabilized neurons was displayed in the ''middle point'' mode showing a single OCR rate for each measurement period. Two measurements were performed under each condition (Base = baseline respiration, S3 = ADP/substrate-stimulated State 3 respiration, S4 o = oligomycin-induced State 4 respiration) except for S3 u (the FCCP-stimulated uncoupled State 3 respiration), which consisted of only one measurement. The right bar graph in each panel compares the averaged OCR from the two measurements in each condition among the DMSO-and compound-treated groups. The statistics shown were generated using two-way repeated measure ANOVA with the single control and the experimental groups. Sa = saponin, ADP = adenosine diphosphate, P = pyruvate, M = malate, Succ = succinate, Oligo = oligomycin, FCCP = carbonyl cyanide-ptrifluoromethoxyphenylhydrazone, AA = antimycin, R = rotenone. Note: We recently reported the experimental results for dyclonine , performed in parallel with yohimbine and doxepin as reported here. Thus the DMSO data shown are replicated from Varkuti et al. (2020) . Statistical significance data were obtained from the DMSO control and all three experimental groups (yohimbine, doxepin, dyclonine). (C-D 0 ) Respiration of mitochondria isolated from brain neurons. Brain mitochondria were isolated from C57BL/6J animals administered either compoundsupplemented (5 mg/kg yohimbine) or standard water for 7 months starting at 2 months of age. State 3 respiration was stimulated by addition of ADP (1 mM). Complex I substrates pyruvate and malate (P/M) or the Complex II substrate succinate (Succ) were preincluded in the assay buffer at 10 mM before the measurement of baseline respiration to maintain the healthy state of isolated mitochondria. OCR measured from isolated brain mitochondria is displayed in the ''point-to-point mode'' showing a series of OCR rates across each measurement period. The right bar graph in each panel compared the OCR value of the first measured point in each condition between the water-and compound-treated groups. Total protein was determined using the BCA assay (Bicinchoninic Assay) and used to normalize OCR into pmol O 2 /min/mg total protein. Results in all panels are plotted as the mean G SEM (n = 11-12). Data were analyzed by two-way repeated measure ANOVA followed by Bonferroni's multiple comparison tests. *p < 0.05, ***p < 0.001, ****p < 0.0001 compared with corresponding controls.
invite the speculation that the therapeutic effects of tricyclic antidepressants and anti-psychotics might include the functional modulation of brain mitochondria. On the technical side, our results show the feasibility of screening large libraries of compounds for effects on mitochondrial function directly in neurons, providing a more biologically relevant HTS platform for use in brain disease research.
Elucidating the mechanisms of action that these molecules have on the mitochondrial system in neurons is a long-term task, but prior studies offer a few intriguing possibilities. Estrogen derivatives (Cluster 4) and the , the circularity and length of mitochondria and the area of neurites in images were quantified after segmentation (e.g., extraction of neuritic area with ImageJ, fourth column of images). DIV13 neurons were treated with selected TMRM/ATP hit compounds or DMSO vehicle control and imaged after 24 or 48 h. Scale bar, 20 mm. (B) Neuritic mitochondria, which vary in length, were classed into axonal mitochondria (0.5 mm % length %1.4 mm) and dendritic mitochondria (length R2.4 mm) based on our prior studies . The circularity of axonal mitochondria and the length of dendritic mitochondria were measured using the GFP signal and the neurite area from segmenting tdTomato fluorescence. These parameters were normalized as robust Z scores relative to in-plate, DMSO control wells. Data are presented as means G SEM (n = 12 wells). indole alkaloids (Cluster 5) have been reported to contain potent neuro-and mitochondrial-protective activity. This may occur through receptor-independent antioxidant activity, including the reduction of glutamate-induced lipid peroxidation and attenuation of endogenous and exogenous ROS, and/or by receptordependent (ERa, ERb) anti-apoptotic activity, including the regulation of brain-derived neurotropic factor and the mitochondrial targeting of Bcl-2 and Bcl-xL, etc. (Klinge, 2008; Simpkins et al., 2008) . Recently studies have revealed the extranuclear localization of estrogen receptors (ERa, ERb) within mitochondria and the transport of exogenous estrogens into mitochondria (Chen et al., 2008; Psarra and Sekeris, 2008) .
Given that the MicroSource Spectrum compound library consists of a large number of approved drugs, the mechanism of action for the hit compounds has already been explored in the context of the drug's original development. For instance, dyclonine and benoxinate are both local anesthetics that bind reversibly to activated sodium channels decreasing permeability and sensation. Doxepin as a tricyclic antidepressant is a known inhibitor of serotonin and norepinephrine uptake, also inhibiting histamine receptors to relieve local or generalized itching. The atypical anti-psychotic, pimozide, is a selective inhibitor of type 3 dopamine receptors thus decreasing dopaminergic transmission. It is possible, although unlikely, that these mechanisms of action perhaps funnel to some common effector of mitochondrial function and dynamics. However, given the diversity of the compounds identified along with a documented mechanism of action, we think it more likely that multiple known and unknown pathways exist that modulate the complexities of mitochondrial system dynamics and function.
A major future question prompted by this discussion is whether the mitochondrial modulators act directly on mitochondria to produce the observed effects or whether they work indirectly through various signaling systems. None of the data obtained so far address this important question, including the oxygen consumption experiments using mitochondria isolated from the brains of treated mice, because the modulators may have altered cellular signaling to instill long-term changes in mitochondrial function. One way to approach this unknown is to determine whether the modulators produce acute effects on the function of isolated mitochondria, assayed by either ATP generation or oxygen consumption experiments. The identification of distinct mitochondrial protein targets could be approached using photoaffinity-labeled mitochondrial modulators followed by proteomics experiments.
In summary, we have developed a high-throughput assay using primary neuronal cultures for mitochondrial function. Assay development using this cell type is critical for finding small molecule effectors of mitochondrial function given the unique structure and physiology of neurons. A library screen identified a remarkably diverse set of compounds that modulate mitochondrial function that, in addition, alter the mitochondrial dynamic properties of circularity (health) and length and offer protection to the mitochondrial system against two insults associated with neurodegeneration: increased oxidative stress and the neuronal environment found in a mouse model for Alzheimer disease. This set of molecules offers a unique starting point for developing mitotherapeutics to protect the neuronal mitochondrial system from the toxicity associated with neurodegenerative disorders and to probe the intricacies of the mitochondrial system in neurons.
Limitations of the Study
The majority of this study utilized primary neurons from the mouse, which provide an imperfect model for neurons in vivo. Future studies will be directed toward in vivo efficacy of the compounds on the neuronal mitochondrial system. Although many of the compounds identified are known drugs with identified molecular targets, it remains unknown whether these same cellular targets are the ones that produce the observed effects on the mitochondrial system.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100931. 
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Distribution of TMRM
Fluorescence (24 hr Figure 1.  (A, B) Population control for data normalization of TMRM fluorescence. We used a "non-DMSO-control" statistical approach to normalize raw TMRM fluorescence into Z scores and Effect-Size (fold change) for hit identification, based on the fact that the majority of small molecules in HTS assays are absent of biological effects, thus serving as "within plate controls" (Brideau et al., 2003; Malo et al., 2006) . Distribution of TMRM fluorescence from 240 inner wells treated with compounds from source plate 4 at 4 (A) and 24h (B) showing that most of the wells fall into a normal distribution and can be considered to consist of inactive compounds. Some compounds in the inner wells dramatically reduced the TMRM signal and were classified as toxic compounds; others were identified as auto-fluorescent. The wells containing these compounds were not included in the "inactive" population. The plots in (A', B') expand the red-highlighted region in (A,  B) . A bimodal distribution (red line), most obvious in the 24h data set was observed, identifying putative hits in the shoulder peak. The TMRM fluorescence of "inactive" compounds within the dominant peak showed a similar plate mean (µplate) and standard derivation (splate) calculated from inner DMSO-wells in parallel DMSO-only treated plates. This "inactive" population from each plate was used for data normalization. Statistically, this subpopulation was defined by using Tukey's fences rule based on the interquartile range (A', B') . The black dotted line shows the normal distribution of the "inactive" subpopulation with TMRM readouts in the range of [Q1-(Q3-Q1/ITQ), Q3+(Q3-Q1)]. Compounds with activity outside of this range were identified as outliers; Q1 and Q3 represent the first (lower) and third (upper) quartiles respectively. A modified box-and-whiskers plot is illustrated below each distribution. Boxes represent the interquartile range, lines within boxes are medians, whiskers represent values of 1.0 x (interquartile range/ITQ: Q3-Q1) from the first (Q1) and third (Q3) quartiles. (C-E) TMRM assay Z-scores and effect size. The plate mean (µplate) and standard deviation (splate) were calculated using the subpopulation trimmed of outliers to normalize compound performance as Z-scores and Effect Size. Z-scores were calculated by subtracting the µplate, then dividing by the splate ((valuecompoundµplate)/splate). Effect size was calculated by subtracting the µplate, then dividing by the µplate to obtain fold change ((valuecompoundµplate)/µplate). Putative hits from the primary screen were identified as enhancing the well fluorescence above the µplate by 3splate for inner wells, and by 2.5splate for outer wells (Figure 1C-D) . (B-B") Testing the assay using a DMSO source plate. 100 nl DMSO (final concentration ~0.1%) was pintooled into the inner wells of a 384 well microplate. Cellular ATP was measured using the CellTiter-Gloâ luminescence assay (Promega) and the well luminescence measured. The signal of DMSO-treated wells was aggregated by column (B') or by row (B") and plotted. No significant difference in the average luminescence of DMSO wells across the inner columns or rows (one-way ANOVA) was found. Bar plots represent the mean ± the SEM.
(C) Orthogonal screen of putative TMRM hits measuring ATP production. 16 putative hits with effects at 4h (red), and 135 putative hits with effects at 24h (pink) from the primary screen were tested for ATP production alongside 134 randomly selected non-hit compounds (black) and 40 DMSO controls. The main plot shows the correlation of the effect size of TMRM fluorescence and ATP production in wells after 4h of incubation for these compounds. The black line represents the fit using a linear regression model using all plotted compounds (R 2 =0.16, p<0.0001). The compound-induced effect size on ATP production (right histogram) at 4h was normalized to the mean value of the 40 "within-plate" DMSO controls as (valuecompound -µDMSO)/µDMSO. The population of 24h TMRM hits was significantly different from the non-hit population for ATP effect size (right histogram). The 24 and 4h TMRM hit populations were significantly different from the non-hit population for TMRM fluorescence effect size (bottom histogram). The 4h TMRM hits showed a large variation in their effect size on ATP levels (note the distribution of 4h TMRM points), suggesting that acute increases in DYm only weakly correlate with effects on ATP generation. One-way ANOVA followed by Dunn's post hoc to compare among groups, confidence levels were set at *P<0.05, **P<0.01, ***P<0.001. displayed (A,B) with the common core scaffold highlighted in red. We used 15 concentrations from 6 nM to 100 uM for the assays. Points represent the mean ± SEM of 6 independent experiments, with each compound tested in duplicate in each experiment. EC 50 values were calculated from the fitted logistic curve (see Table S2 ). A summary of the dose response curves for compounds tested for both TMRM fluorescence and ATP generation is illustrated at the left for each group for visualizing and comparing the magnitude of TMRM and ATP effect size. displayed (A,B) with the common core scaffold highlighted in red. We used 15 concentrations from 6 nM to 100 uM for the assays. Points represent the mean ± SEM of 6 independent experiments, with each compound tested in duplicate in each experiment. EC 50 values were calculated from the fitted logistic curve (see Table S2 ). A summary of the dose response curves for compounds tested for both TMRM fluorescence and ATP generation is illustrated at the left for each group for visualizing and comparing the magnitude of TMRM and ATP effect size. Dose response assays of compounds in clusters with structural similarity. The 2D-structures of the compounds are displayed (A) with the common core scaffold highlighted in red. We used 15 concentrations from 6 nM to 100 uM for the assays. Points represent the mean ± SEM of 6 independent experiments, with each compound tested in duplicate in each experiment. EC 50 values were calculated from the fitted logistic curve (see Table S2 ). A summary of the dose response curves for compounds tested for both TMRM fluorescence and ATP generation is illustrated at the left for each group for visualizing and comparing the magnitude of TMRM and ATP effect size. Table S1 . Z-scores for hits from the TMRM and ATP screen. Related to Figures 1 and 2 . Listing of the 135 putative hits with Z-scores from the primary screen when assayed at 24h (TMRM Primary, hits: >3 Z-scores for inner wells, >2.5 Z-scores for outer wells), from the rescreen (TMRM Rescreen, hits: >3 Z-scores) and from the ATP orthogonal screen (ATP, hits with >3 Z-scores). Bolded compounds were hits when assayed at 4h as well in the 24h primary screen. Primary hits that were confirmed in the rescreen (120) are listed above the bold line. The 112 hits from the ATP orthogonal screen are listed above the dashed line. 2-5 . *Represents the maximal percent increase of TMRM fluorescence or ATP production relative to in-plate DMSO controls from dose response experiments. Data were generated from 6 independent experiments, with each compound tested in duplicate for each experiment. Significant changes in orthogonal assays are indicated, unless they were nonsignificant (n.s.) or not measured (-).OCR: oxygen consumption rate.
